The assymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis
The assymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis
复制标题
DOI：
10.1054/clnu.2002.0614
复制
发表时间：
2003-02-01
影响因子：
6.3
通讯作者：
Van Leeuwen, PAM
中科院分区：
文献类型：
--
作者：
Nijveldt, RJ;Teerlink, T;Van Leeuwen, PAM
多器官衰竭的发展是危重症患者最复杂的问题，并与高死亡率相关。不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，其临床重要性目前正在揭示。Nijveldt等人（肝脏是不对称二甲基大氨酸（ADMA）代谢的重要器官）临床营养杂志2003；22:17-22)我们发现血浆ADMA浓度在危重患者中升高，且与肝功能显著相关。此外，血浆ADMA浓度成为这些患者ICU死亡率的一个强大且独立的危险因素。在这里，我们假设ADMA的积累是通过干扰一氧化氮生成的重要生理功能而导致多器官功能衰竭的一个致病因素。2003爱思唯尔科学有限公司版权所有。
Development of multiple organ failure is the most complex problem in critically ill patients, and is associated with a high mortality. Asymmetrical dimethylarginine (ADMA) is an endogenously produced inhibitor of nitric oxide synthase, of which the clinical importance is currently being revealed. In Nijveldt et al. (The liver is an important organ in the metabolism of asymmetrical dimethylargenine (ADMA) Clin Nutr 2003; 22:17-22) we showed that plasma ADMA concentration is elevated in critically ill patients and significantly related to hepatic function. Moreover, plasma ADMA concentration emerged as a strong and independent risk factor for ICU mortality in these patients. Here, we hypothesize that accumulation of ADMA is a causative factor in the development of multiple organ failure by interfering with important physiological functions of nitric oxide production. (C) 2003 Elsevier Science Ltd. All rights reserved.